Pangaea Data Awarded Top Tier Co-Sell Partnership Status by Microsoft

Microsoft and UK DIT Selects Pangaea to Showcase at HLTH

Global Pharmaceutical Proves Pangaea’s AI

Pangaea is Selected by the UK Government as a Leading Digital Health Innovator

Go back

Pangaea Data Awarded Top Tier Co-Sell Partnership Status by Microsoft

Microsoft has also selected Pangaea to showcase during the HLTH conference in Las Vegas from Nov 13-16th 2022, booth 1858-9.

South San Francisco, USA, 07 November 2022: Pangaea Data, (Pangaea), provider of a novel AI-driven product for characterizing patients by mapping their journeys and disease trajectories in a privacy-preserving and scalable manner, today announced that it has been awarded top tier co-sell partnership status by Microsoft, its highest level partner designation. Microsoft has also extended this status by making Pangaea a transactable solution through the Azure marketplace.

With a joint global go-to-market co-selling strategy, the Microsoft co-sell program enables Pangaea to work together with Microsoft’s sales organization to rapidly accelerate the sales and usage of Pangaea’s novel AI-driven product on Microsoft Azure. 

Dr Vibhor Gupta, CEO and Founder of Pangaea, said:We launched Pangaea to help improve patient outcomes by providing clinicians across the global pharmaceutical and healthcare industry the ability to characterize patient journeys and disease trajectories by unlocking and summarizing clinical insights from their records in a privacy-preserving and scalable manner. Achieving co-sell ready status reflects our growing relationship with Microsoft through the value we have generated for clinicians and patients since joining the Microsoft for Startups program. We are proud of this accomplishment, which will help us accelerate and scale our work across the pharmaceutical industry and healthcare providers in a privacy-preserving manner.”

Sally Frank, Worldwide Lead, Healthcare and Life Sciences at Microsoft for Startups, said:We are excited to have Pangaea as a co-sell ready partner, a status which the Company has achieved in record time, and for its product to be transactable through the Azure marketplace. Pangaea continues to demonstrate its value for the healthcare and life science industry. We want to contribute and be part of the Company’s journey so that we can help clinicians as they process more patient data in a secure and compliant manner on Azure.”

Register to meet Pangaea at the HLTH conference from November 13th – 16th here.

Media enquiries

Email: pr@pangaeadata.ai

About Pangaea:

Pangaea Data is a South San Francisco and London based provider of novel AI-driven products for characterizing patients by mapping their journeys and disease trajectories in a privacy-preserving and scalable manner, which has clinically proven to discover 20x more undiagnosed, misdiagnosed and miscoded patients; 5x more suitable clinical trials; and new insights across rare and hard-to-diagnose conditions, resulting in 50% reduction of treatment costs; 90% saving in operational costs and time; and sustainable collaborations between healthcare and the pharmaceutical industry. The founders (Dr. Vibhor Gupta and Prof. Yike Guo) have attracted more than $200 million through their research. The company is advised by leading authorities from life sciences and healthcare like Lord David Prior (former Chairman of NHS England and Vice Chairman of Lazards) and Mr. Andy Palmer (former Head of Systems Integration at Novartis and a prolific serial entrepreneur) and has published its work in high-impact, peer-reviewed journals and at conferences.